Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

NCT05203965 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05203965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
Lead sponsor
Yale University
Phase
Phase 1
Overall status
Completed
Start date
May 17, 2022
Completion date
May 31, 2026
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

familial alcoholism vulnerability